Acceleron Pharma
Merck & Co., Inc. is a global healthcare company dedicated to discovering, developing, and providing innovative medicines, vaccines, and health solutions. With a history spanning over 130 years, Merck operates responsibly to enable a safe and healthy future for people and communities worldwide. The company is committed to scientific innovation, sustainability, and improving access to healthcare. Merck's mission is to solve some of the world's biggest health challenges through science and innovation.
Industries
Nr. of Employees
medium (51-250)
Acceleron Pharma
Cambridge, Massachusetts, United States, North America
Patents
Transforming growth factor-beta (TGF-beta) receptor type II fusion polypeptides
US-12195519-B2
View Details
Transforming growth factor-beta (TGF-beta) receptor type II fusion polypeptides
US-12195519-B2
View DetailsProducts
Pharmaceutical pipeline (small molecules, biologics, vaccines)
A disclosed portfolio of investigational and approved therapeutics across oncology, vaccines, infectious diseases, cardio‑metabolic disorders, immunology, neuroscience and ophthalmology.
Access and licensing programs for medicines
Programs and agreements to expand access to medicines, including voluntary licensing with generic manufacturers and patient assistance information.
Pharmaceutical pipeline (small molecules, biologics, vaccines)
A disclosed portfolio of investigational and approved therapeutics across oncology, vaccines, infectious diseases, cardio‑metabolic disorders, immunology, neuroscience and ophthalmology.
Access and licensing programs for medicines
Programs and agreements to expand access to medicines, including voluntary licensing with generic manufacturers and patient assistance information.
Services
Research collaborations, exclusive licenses and co-development agreements with biotech and academic partners to discover and advance therapeutic candidates.
Operational support for planning and running clinical studies across therapeutic areas, including trial listings and patient recruitment resources.
Equity investments and strategic relationships with data and informatics companies to support oncology research and care-improvement initiatives.
Partnerships to integrate clinical records with linked biospecimens and analytic platforms to support target discovery and translational research.
Collaborative programs to engineer enzymes for use as biocatalysts and integrate them into API manufacturing workflows.
Collaborative use of functional/phenotypic screening platforms to discover and validate modulators of therapeutic targets for oncology and neurology programs.
Research collaborations, exclusive licenses and co-development agreements with biotech and academic partners to discover and advance therapeutic candidates.
Operational support for planning and running clinical studies across therapeutic areas, including trial listings and patient recruitment resources.
Equity investments and strategic relationships with data and informatics companies to support oncology research and care-improvement initiatives.
Partnerships to integrate clinical records with linked biospecimens and analytic platforms to support target discovery and translational research.
Collaborative programs to engineer enzymes for use as biocatalysts and integrate them into API manufacturing workflows.
Collaborative use of functional/phenotypic screening platforms to discover and validate modulators of therapeutic targets for oncology and neurology programs.
Expertise Areas
- Clinical trial management
- Diversity in clinical research
- AI-driven drug discovery and generative AI
- Antibody and protein therapeutic development
Key Technologies
- Generative AI / GenAI for target and candidate design
- Machine learning/deep learning for antibody and protein design
- Synthetic biology for therapeutic engineering
- Oligonucleotide discovery platforms
News & Updates
The FDA has approved Merck's Enflonsia Clesrovimab for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants.
Merck has entered into an exclusive license and research collaboration with Aligos Therapeutics to develop oligonucleotides targeting NASH and other cardiometabolic/fibrosis targets.
Merck reports strong financial results for the first quarter of 2025, driven by growth in key therapeutic areas.
Merck announces new initiatives to improve access and outcomes in cancer care worldwide.
FDA Approval of RSV Prevention Monoclonal Antibody
Merck's monoclonal antibody for RSV prevention received FDA approval, marking a significant achievement in infectious disease treatment.
Recognition for Sustainability Efforts
Merck received awards for its sustainability and corporate responsibility programs.
The FDA has approved Merck's Enflonsia Clesrovimab for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants.
Merck has entered into an exclusive license and research collaboration with Aligos Therapeutics to develop oligonucleotides targeting NASH and other cardiometabolic/fibrosis targets.
Merck reports strong financial results for the first quarter of 2025, driven by growth in key therapeutic areas.
Merck announces new initiatives to improve access and outcomes in cancer care worldwide.
FDA Approval of RSV Prevention Monoclonal Antibody
Merck's monoclonal antibody for RSV prevention received FDA approval, marking a significant achievement in infectious disease treatment.
Recognition for Sustainability Efforts
Merck received awards for its sustainability and corporate responsibility programs.